# ASTRA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astra-therapeutics

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.astratherapeutics.com
- Total disclosed funding: $9.8M
- Latest round: Seed (Jul 24, 2025)
- Investors on record: 5

## About

Based in Switzerland, ASTRA Therapeutics operates in the biotechnology sector, focusing on the development of innovative therapeutic solutions that address critical medical needs across various disease states.ASTRA Therapeutics is a biotechnology company that develops therapeutic solutions for various diseases. Founded in 2019, the company has pivoted towards innovative drug delivery systems and biologic therapies. The headquarters is located in Switzerland. The firm raised CHF 7.75 million in a Seed funding round on July 24, 2025, co-led by MIG Verwaltungs AG and Digitalis Ventures, with participation from Borealis Ventures, Kickfund, and Venture Kick. This funding round represents the total amount raised to date.Astra Therapeutics focuses on developing innovative therapeutic solutions aimed at addressing critical medical needs within various disease states. Their flagship products target specific pathophysiological mechanisms, providing enhanced treatment efficacy for patients suffering from chronic illnesses. The company’s core offerings are centered around advanced drug delivery systems and biologic therapies intended to improve patient outcomes. Astra Therapeutics primarily serves healthcare providers, hospitals, and specialized clinics within the United States and Europe, delivering solutions for physician-directed therapies and patient self-administration. Their products are utilized in treating conditions such as autoimmune disorders and rare diseases, with plans to expand into emerging markets in Asia and Latin America.Astra Therapeutics generates revenue through direct sales and partnerships with healthcare institutions and pharmaceutical distributors. Their business model relies on B2B transactions where hospitals and clinics order innovative therapies, ensuring a steady supply within the healthcare ecosystem. The company collaborates with research organizations and pharmaceutical companies through strategic partnerships, including co-development agreements and licensing arrangements for proprietary technologies. The pricing structure for their products reflects the complexity and therapeutic value of each solution, positioning them competitively in the market and supporting long-term relationships with healthcare providers.Astra Therapeutics plans to utilize the CHF 7.75 million raised in their Seed funding round to accelerate the development of precision parasiticides for animal health. The company is also targeting expansion into new geographic regions, particularly in Asia and Latin America, focusing on launching new products designed to meet emerging market demands in the near future.

## Funding rounds

- Seed, Jul 24, 2025, $9.8M — Borealis Ventures, MIG Capital, Digitalis Ventures, Venture Kick, Kickfund

## Investors

- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Seed
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Seed
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Seed
- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- Kickfund (https://capitalatlas.ai/funds/kickfund) — Seed